SCHEMBL856198

SCHEMBL856198

[c]1nc(SCc2ccccc2)nc2c1CCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
NPC1 O15118 3/20 0.56
L3MBTL1 Q9Y468 3/20 0.56
KDM1A O60341 1/20 0.43
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 6/20 0.42
NPSR1 Q6W5P4 5/20 0.42
PPARG P37231 2/20 0.42
NCOA2 Q15596 2/20 0.42
TP53 P04637 2/20 0.42
NCOA1 Q15788 1/20 0.42
ESR2 Q92731 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
NCOA3 Q9Y6Q9 1/20 0.42
ALOX15 P16050 1/20 0.42
HSP90AA1 P07900 1/20 0.41
KDM4E B2RXH2 2/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL856770 0.71 L3MBTL1 (0.71) RAB9ASMN1; SMN2NPC1L3MBTL1KDM1A
SCHEMBL13752162 0.68 RAB9A (0.70) RAB9ASMN1; SMN2NPC1L3MBTL1HSD17B10
SCHEMBL1029180 0.61 HSD17B10 (1.00) RAB9ASMN1; SMN2NPC1HSD17B10ALDH1A1
SCHEMBL883092 0.61 NPC1 (0.44) RAB9ASMN1; SMN2NPC1L3MBTL1HSD17B10
SCHEMBL11615149 0.61 RAB9A (0.59) RAB9ASMN1; SMN2NPC1L3MBTL1HSD17B10
SCHEMBL5888974 0.61 RAB9A (0.59) RAB9ASMN1; SMN2NPC1L3MBTL1HSD17B10
SCHEMBL29043729 0.61 HSD17B10 (0.68) RAB9ASMN1; SMN2NPC1HSD17B10ALDH1A1
SCHEMBL7100530 0.61 HSD17B10 (0.52) RAB9ASMN1; SMN2NPC1HSD17B10ALDH1A1
SCHEMBL9442103 0.60 POLB (0.50) RAB9ASMN1; SMN2NPC1L3MBTL1HSD17B10
SCHEMBL5450296 0.60 RAB9A (0.68) RAB9ASMN1; SMN2NPC1HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA RAB9A 1023/4885SMN1; SMN2 3705/4885NPC1 1583/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA RAB9A 720/4885SMN1; SMN2 3818/4885NPC1 1273/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA RAB9A 1064/4885SMN1; SMN2 3798/4885NPC1 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.